[1] Nuccil M, Marr KA. Emerging fungal diseases[J]. Clin Infect Dis, 2005, 41(4):521-526.[2] Boschman CR, Bodnar UR, Tornatore MA, et al. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center[J]. Antimicrob Agents Chemother, 1998, 42(4):734-738.[3] 冷萍,郭秀丽,娄红祥.真菌耐药的分子机制及新型抗真菌药物[J].生理科学进展, 2005, 36(4):325-328.[4] Koltin Y, Hitchcock CA. Progress in the search for new triazole antifungal agents[J]. Curr Opin Chem Biol, 1997, 1(2):176-182.[5] Gallis HA, Drew RH, Pickard WW. Amphotericin B:30 years of clinical experience[J]. Rev Infect Dis,1990, 12(2):308-329.[6] Gallis HA. Amphotercin B:a commentary on its role as an antifungal agent and as a comparative agent in clinical trials[J]. Clin Infect Dis, 1996, 22(Suppl 2):S145-S147.[7] Li LJ, Ding H, Wang BG, et al. Synthesis and evaluation of novel azoles as potent antifungal agents[J]. Bioorg Med Chem Lett, 2014, 24(1):192-194.[8] National Committee for Clinical Laboratory Standards, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved standard[S]. Document M27-A2, National Committee for Clinical Laboratory Standards, Wayne, PA, 2002.[9] Chai XY, Zhang J, Hu HG, et al.Design, synthesis, and biological evaluation of novel triazole derivatives as inhibitors of cytochrome P45014α-demethylase[J]. Eur J Med Chem, 2009, 44(5):1913-1920.
[2] Chai XY, Zhang J, Yu SC, et al. Design, synthesis, and biological evaluation of novel 1-(1H-1,2,4-triazole-1-yl)-2- (2,4-difluorophenyl)-3-substituted benzylamino-2-propanols[J]. Bioorg Med Chem Lett, 2009, 19(6):1811-1814.
[3] Chai XY, Zhang J, Cao YB, et al.Design, synthesis and molecular docking studies of novel triazole as antifungal agent[J]. Eur J Med Chem, 2011, 46(7):3167-3176.
[4] Chai XY, Yang G, Zhang J, et al. Synthesis and biological evaluation of triazole derivatives as potential antifungal agent[J]. Chem Biol Drug Des, 2012, 80(3):382-387.
[5] Yu SC, Chai XY, Wang YW, et al. Triazole derivatives with improved in vitro antifungal activity over azole drugs[J]. Drug Des Devel Ther, 2014, 8:383-390.
[6] Zou Y, Yu SC, Li RW, et al. Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl) -2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates[J]. Eur J Med Chem, 2014, 74(4):366-374.